We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Regeneron's Antibody Cocktail Could Be Used to Treat as Well as Prevent COVID-19, Finds Study

By HospiMedica International staff writers
Posted on 13 Oct 2020
Print article
Image: Novel Coronavirus SARS-CoV-2 (Photo courtesy of NIAID)
Image: Novel Coronavirus SARS-CoV-2 (Photo courtesy of NIAID)
Regeneron Pharmaceuticals, Inc.’s (Tarrytown, NY, USA) antibody cocktail has been found to be effective in reducing COVID-19 symptoms in rhesus macaques and golden hamsters prior to infection as well as after infection with the SARS-CoV-2 virus, suggesting that REGN-COV2 may offer therapeutic benefits both as a treatment and as a preventative measure for COVID-19.

In studies conducted by researchers at the Texas Biomedical Research Institute (San Antonio, TX, USA), Regeneron’s COVID-19 antibody cocktail was administered to rhesus macaques and golden hamsters. In the first part of the study, the researchers injected healthy rhesus macaques with the SARS-CoV-2 virus and administered REGN-COV2 three days later to see if the treatment had any impact. The group of monkeys who had received the antibody cocktail treatment prior to infection showed far fewer symptoms compared to the control group and also had a much lower viral load.

In the second part of the study, the researchers administered REGN-COV2 to some rhesus macaques after they were infected with the SARS-CoV-2 virus and found that the antibody cocktail treatment reduced their symptoms as well as resulted in faster viral clearance. Similar experiments performed on golden hamsters revealed that administering REGN-COV2 two days before they were infected with the SARS-CoV-2 virus greatly reduced their symptoms. Hamsters who were administered REGN-COV2 after being infected with the SARS-CoV-2 virus also exhibited a reduction in symptoms and faster viral clearance. Based on these findings, the researchers have suggested that Regeneron’s antibody cocktail, REGN-COV2, could offer therapeutic benefits as a treatment as well as preventative measure for COVID-19.

Separately, Regeneron’s CEO Leonard Schleifer has said that the company’s experimental drug cocktail for the treatment of COVID-19 “does” create immunity, although it was not known how long the immunity would last. In an interview with CBS News, Schleifer said REGN-COV2 could provide immunity against COVID-19 for months or even years.

“Could be months, could be years,” said Schleifer. “If you get it in our vial, if you will, that’s probably going to last you for months.”

Related Links:
Regeneron Pharmaceuticals, Inc.
Texas Biomedical Research Institute


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Guide Wire
E-wire

Print article

Channels

Critical Care

view channel
Image: The °M Warmer portable blood & IV fluid warmer has received US FDA 510(k) regulatory clearance (Photo courtesy of °MEQU)

Portable System for Warming Blood and IV-Fluids Reduces Hypothermia Risk in Hemorrhaging Patients

Maintaining a normothermic temperature in patients is often challenging. Accidental hypothermia is a known risk that can lead to increased complications and extended hospital stays. One key factor contributing... Read more

Surgical Techniques

view channel
Image: New studies suggest benefit of total robotic metabolic and bariatric surgery over conventional laparoscopy (Photo courtesy of 123RF)

Total Robotic Metabolic and Bariatric Surgery Proves More Beneficial than Conventional Laparoscopy

According to the U.S. Centers for Disease Control and Prevention (CDC), 42.4% of Americans are affected by obesity. Research indicates that obesity can compromise the immune system, trigger chronic inflammation,... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more